Liraglutide is a peptide that has gained significant attention in scientific research due to its structural similarity to ...

Health Canada Authorizes 4Moving Biotech to Launch Phase 2a INFLAM MOTION Clinical Trial for Knee Osteoarthritis ...

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

BRP, identified through peptide prediction, may revolutionize weight loss treatment, offering efficacy without the ...

Use of cutting-edge weight-loss drugs like Ozempic and Zepbound has increased dramatically among people with type 1 diabetes, raising safety concerns among experts, a new study says.

(RTTNews) - OPKO Health (OPK) and Entera Bio have entered a collaboration and license agreement to develop the first oral dual agonist GLP-1/glucagon ... oxyntomodulin analog (OPK-88006) with ...

4P004 is a GLP-1 analog, tailored for intra-articular use in knee osteoarthritis. It was developed to exploit the analgesic, anti-inflammatory, anti-catabolic, and anabolic benefits of GLP-1.